Author:
Luo Xinyu,Wang Nan,Xing Yue,Gao Xinyue,Yu Yang,Liu Tong,Jiang Shuai,Dong Mei
Funder
Scientific Research Project of Heilongjiang Provincial Health and Health Commission
Heilongjiang Postdoctoral General Program
Health Development Promotion Project of Beijing Kangmeng Charity Foundation
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. US Food and Drug Administration (FDA) (2017) HERCEPTIN® (trastuzumab) US Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103792s5337lbl.pdf. Accessed 7 Apr 2023
2. Boekhout AH, Beijnen JH, Schellens JH (2011) Trastuzumab Oncologist 16(6):800–810
3. Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ (2015) A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat 151(1):27–40
4. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62(14):4132–4141
5. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE (2000) ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20(9):3210–3223